Kidney Cancer | Tumor

CURE’s kidney cancer page is an extensive resource of cancer information featuring the latest kidney cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on kidney cancer.

In Understanding Kidney Cancer Treatments, ‘Knowledge Is Power’

September 21st 2021

Patients and caregivers of those with kidney cancer can become active members in their care by staying up to date on the latest treatments and medical advances.

Lack of Smoking Data in Bladder, Kidney and Prostate Cancer Clinical Trials May Affect Patient Outcomes

September 17th 2021

Clinical trials that are designed to ask patients with bladder, kidney and prostate cancer about their smoking status may help patients better understand what to expect from their treatment based on their smoking habits.

Novel Combinations Offer New Hope in Kidney Cancer

September 13th 2021

Immunotherapy and tyrosine kinase inhibitors may potentially change the treatment paradigm for patients with renal cell carcinoma, the most common type of kidney cancer in adults.

Cholesterol-Blocking/Hepatitis C Antiviral Drugs May Work on Kidney Cancer

August 26th 2021

Inhibiting a cholesterol receptor could prevent a certain type of kidney cancer from growing, according to recent research.

FDA’s Welireg Approval A ‘Complete Game Changer’ for Certain Cancers Associated With VHL Disease

August 24th 2021

The approval of Welireg, according to an expert at Massachusetts General Hospital, is “extremely important” and will “dramatically” change how certain von Hippel-Lindau-associated cancers are treated.

Keytruda-Lenvima Combo for Advanced Renal Cell Carcinoma Signifies ‘a Great Time for the Field’

August 20th 2021

Frontline Keytruda plus Lenvima for advanced renal cell carcinoma is an effective treatment with life-prolonging benefits, although patients should be monitored for side effects that can be easily managed.

FDA Approves Welireg for Several Cancers Associated With VHL Disease

August 13th 2021

The FDA granted approval to Welireg for the treatment of patients with von Hippel-Lindau-associated kidney cancer, CNS hemangioblastomas and pancreatic neuroendocrine tumors.

FDA Approves Keytruda Plus Lenvima for Frontline RCC Treatment

August 12th 2021

Patients on Keytruda/Lenvima lived for an average of 23.9 months without their disease progressing, compared to those on a different treatment, with an average of 9.3 months.

FDA Grants Keytruda Priority Review for Kidney Cancer Treatment

August 10th 2021

The FDA will speed up the review of Keytruda to treat patients with kidney cancer after they’ve undergone surgery.

Women With Diabetes May Face Increased Kidney Cancer Risk

July 26th 2021

Post-menopausal women may be at an increased risk for kidney cancer if they are diagnosed with type 2 diabetes.

Inequality in Kidney Cancer Treatment Affects Decision-Making

July 19th 2021

The risk for under- or over-treatment for kidney cancer may be higher in women, in addition to Black and Hispanic patients.

Minnesota Congressman Jim Hagedorn’s Cancer Returned, A Three-time Survivor Plans to Bike 100 Miles and More

July 9th 2021

From the recurrence of congressman Jim Hagedorn’s kidney cancer to a 100-mile bike race for charity, here’s what’s happening in the cancer landscape this week.

Lenvima-Keytruda Combo Shows Superior Benefit Over Sutent Across Several Subgroups of Patients with Kidney Cancer

June 28th 2021

The combination of Lenvima and Keytruda was associated with improvements in survival and response rates over Sutent alone in various subgroups of patients with advanced renal cell carcinoma.

Novel Drug Induces Robust Responses in von-Hippel Lindau Disease-Associated Kidney Cancer

June 24th 2021

At a median follow-up of almost two years, 88.5% of patients remained on study treatment.

Man With Late-Stage Cancer Gets Matching Tattoos with Strangers, Elderly Cancer Survivor Earns Black Belt in Taekwondo

June 18th 2021

From a man with late-stage cancer who has matching tattoos with over 400 strangers to a 78-year-old cancer survivor getting his black belt in Taekwondo, here’s what’s happening in the cancer landscape this week.

Keytruda-Inlyta Combo Continues to Improve Survival in Kidney Cancer

June 10th 2021

Use of the combination of Keytruda and Inlyta is associated with long-term survival benefits in patients with kidney cancer.

Fotivda Nearly Doubles Duration of Response Compared With Nexavar in Metastatic Kidney Cancer

June 6th 2021

In patients with metastatic renal cell carcinoma whose disease failed to respond to two prior therapies, Fotivda, compared with Nexavar, contributed to a duration of response of 20.3 months versus 9 months.

Keytruda After Surgery Significantly Improves Survival in Patients with Kidney Cancer

June 4th 2021

Treatment with Keytruda following surgery was associated with a significant reduction in the risk of disease recurrence or death compared with placebo in patients with clear cell renal cell carcinoma.

FDA Grants Keytruda-Lenvima Combo Priority Review for Treatment of Advanced Kidney Cancer and Endometrial Cancer

May 6th 2021

The priority review will focus on the combination of Keytruda and Lenvima for the first-line treatment of advanced renal cell carcinoma, as well as the treatment of certain patients with endometrial carcinoma.

Higher BMI May Be Associated With Improved Overall Survival in Patients with Metastatic Kidney Cancer

April 22nd 2021

Recent data found an association between higher BMI and better overall survival among patients with metastatic renal cell carcinoma who were treated with immune checkpoint inhibitors.

Active Surveillance Occurs Frequently Versus Systemic Therapy for Metastatic Renal Cell Carcinoma

April 20th 2021

Certain patients with metastatic renal cell carcinoma may benefit with active surveillance compared with systemic therapy for their management and may also lead to an improved quality of life.

Inlyta Shows Promise for Metastatic Clear Cell Renal Cell Carcinoma

April 19th 2021

Inlyta alone demonstrates longer progression-free survival compared to Inlyta in combination with carotuximab.

NCCN Recommends Lenvima Plus Keytruda for First-Line Renal Cell Carcinoma: What Patients Should Know

April 9th 2021

CURE spoke with Dr. Eric Jonasch about the National Comprehensive Cancer Network’s Category 1 recommendation for the combination use of Lenvima plus Keytruda for the treatment of front-line renal cell carcinoma. In particular, how it can impact a patient’s treatment journey.

FDA’s Fotivda Approval Provides Certain Patients With Kidney Cancer ‘Another Future Treatment Option’

March 24th 2021

The biggest reason the FDA’s recent approval of Fotivda is important for adults with relapsed or refractory advanced renal cell carcinoma who have received two or more prior systemic therapies, according to an expert from the Vanderbilt-Ingram Cancer Center, is that it offers them a very tolerable treatment option that may preserve quality of life.

Recent News and Updates in Kidney Cancer

March 15th 2021

In honor of Kidney Cancer Awareness Month, CURE® compiled some recent kidney cancer news and updates patients may have missed.

FDA Approves Fotivda for Kidney Cancer Subset

March 10th 2021

The agency granted approval to Fotivda in adults with relapsed or refractory advanced renal cell carcinoma who have received two or more prior systemic therapies.

Cabometyx-Opdivo Is ‘One of the New Standards of Care’ in Treating Kidney Cancer Subtype

March 9th 2021

The combination of Cabometyx (cabozantinib) plus Opdivo (nivolumab) “is certainly going to become one of the new standards of care” for the treatment of advanced renal cell carcinoma now that the regimen is approved, according to an expert from the Dana-Farber Cancer Institute.

Immunotherapy Combinations Offer ‘Hope and Promise’ for Patients with Advanced Renal Cell Carcinoma

February 23rd 2021

Positive results from the phase 3 CLEAR clinical trial, presented at the 2021 ASCO Genitourinary Cancers Symposium, are just one more dataset that could offer “a sense of hope and promise” for patients with advanced renal cell carcinoma (RCC), says the study’s lead author, Dr. Robert J. Motzer.

Newly a Mom, Kayla Got a Cancer Diagnosis

February 23rd 2021

In June 2020, Kayla Bulkley gave birth to her and her husband’s long-awaited baby girl, Jane. Within a month, Kayla was diagnosed with kidney cancer.

Cabometyx Significantly Prolongs Survival Over Sutent in Rare Form of Kidney Cancer

February 18th 2021

The study results, according to one expert, show that Cabometyx should be considered the new standard for systemic therapy in patients with metastatic papillary renal cell carcinoma.

NEXT PAGE
PREVIOUS PAGE